Edwards Lifesciences Corp

Most Recent

  • uploads///eps
    Earnings Report

    What to Expect from St. Jude Medical’s Earnings in 2Q16

    In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.

    By Sarah Collins
  • uploads///projections
    Earnings Report

    Becton, Dickinson and Company’s 4Q16 Earnings Estimates

    Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.

    By Sarah Collins
  • uploads///DIABETES
    Earnings Report

    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

    By Sarah Collins
  • uploads///thv
    Earnings Report

    What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?

    Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Earnings Report

    Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results

    Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.

    By Sarah Collins
  • uploads///diabetes _
    Earnings Report

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”

    By Sarah Collins
  • uploads///stock performance
    Earnings Report

    Abbott Laboratories’ Stock Price Performance in July

    Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.

    By Sarah Collins
  • uploads///hospital _
    Earnings Report

    Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings

    On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.

    By Sarah Collins
  • uploads///hand __
    Company & Industry Overviews

    BSX Stock Regains Momentum after Its Recent Bearish Trend

    On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.

    By Sarah Collins
  • uploads///hospital _
    Company & Industry Overviews

    Boston Scientific Stock in the Week Ended September 14

    Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.

    By Sarah Collins
  • uploads///Grph
    Company & Industry Overviews

    Can Edwards Lifesciences See Robust Net Profit Margin in 2017?

    In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.

    By Margaret Patrick
  • uploads///microbiology _
    Company & Industry Overviews

    Illumina Stock Continues Its Bull Run

    Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.

    By Sarah Collins
  • uploads///ABMD
    Company & Industry Overviews

    Examining Abiomed’s Gross Margin Trend

    In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.

    By Kenneth Smith
  • uploads///equipment _
    Company & Industry Overviews

    Boston Scientific and Edward Lifesciences Settle Patent Dispute

    Today, Boston Scientific (BSX) is trading at $36.76, which is a ~4.11% increase from yesterday’s closing price.

    By Daniel Collins
  • uploads///ABMD
    Company & Industry Overviews

    Do Analysts See Any Upside for Abiomed Stock?

    In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Exploring Abiomed’s Latest Performance Trends

    In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.

    By Kenneth Smith
  • uploads///BSX
    Company & Industry Overviews

    Why Analysts Are Mostly Positive on Boston Scientific Stock

    Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.

    By Daniel Collins
  • uploads///hypertension _
    Company & Industry Overviews

    Taking Stock of Edwards Lifesciences’ Performance

    A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///NVCR ana reco
    Earnings Report

    Gauging Analysts’ Views for NovoCure Stock

    Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”

    By Kenneth Smith
  • uploads///earnings estimates
    Earnings Report

    Edwards Lifesciences’ Q3 2018 Earnings Estimates

    Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.

    By Sarah Collins
  • uploads///sales estimates
    Earnings Report

    What to Expect of Edwards Lifesciences’ Q3 2018 Sales

    Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.

    By Sarah Collins
  • uploads///COMPARISON
    Company & Industry Overviews

    EW Stock Returned More than the S&P 500’s Gain in 2018

    As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    High Valuation Multiples: Is EW Stock an Expensive Bet?

    On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.

    By Sarah Collins
  • uploads///COMPARISON
    Company & Industry Overviews

    ABT Returns Almost Double the S&P 500’s Year-to-Date Gain

    As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).

    By Sarah Collins
  • uploads///mitraclip
    Company & Industry Overviews

    MitraClip Drives Growth, Gets Reimbursement Approval in Japan

    On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.

    By Sarah Collins
  • uploads///masters hp
    Company & Industry Overviews

    ABT Gets FDA Approval for World’s Smallest Mechanical Heart Valve

    Abbott announced that it received FDA approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    BSX Stock Rises More Than 2% Following EMcision Acquisition

    Boston Scientific’s recent stock performance On March 6, 2018, Boston Scientific (BSX) stock closed at $27.41, higher than its 50-day moving average of $27.15 and lower than its 200-day moving average of $27.52. As of March 7, 2018, Boston Scientific’s 52-week high was $29.93 on October 23, 2017, and its 52-week low was $24.02 on March 22, 2017. Factors […]

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Wall Street’s Recommendations and Target Prices for BSX

    Analysts’ recommendations on Boston Scientific Boston Scientific (BSX) is a leading medical technology company in the United States. The company has been a leading player in minimally invasive therapies for a range of cardiovascular and rhythm management diseases, a space that has become increasingly competitive over the years. Boston Scientific has been expanding in other areas, including endoscopy under its MedSurg […]

    By Sarah Collins
  • uploads///EW revenue
    Company & Industry Overviews

    Analyzing Edwards Lifesciences’ Recent Acquisitions

    In December 2017, Edwards Lifesciences (EW) acquired Harpoon Medical for a total consideration of $119.5 million.

    By Kenneth Smith
  • uploads///EW product areas
    Company & Industry Overviews

    Edwards Lifesciences’ Strong Product Portfolio Bodes Well

    Edwards Lifesciences’ (EW) products can be categorized into three therapeutic areas: transcatheter heart valve, surgical heart valve, and critical care.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    What Analysts Recommend for Edwards Lifesciences

    Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating.

    By Kenneth Smith
  • uploads///MMSI revenue
    Company & Industry Overviews

    Exploring Merit Medical Systems’ Business Segments

    In 3Q17, Merit Medical Systems’ cardiovascular segment generated revenues of $172.7 million—compared to $150.5 million in 3Q16.

    By Kenneth Smith
  • uploads///doctors office checkup medical
    Company & Industry Overviews

    Merit Medical Systems: Analysts’ Ratings in February 2018

    Of the eight analysts covering Merit Medical Systems in February, four gave it a “strong buy,” three gave it a “buy,” and one gave it a “sell” rating.

    By Kenneth Smith
  • uploads///mitg
    Earnings Report

    Medtronic’s Minimally Invasive Therapies Group in 3Q18

    Overview In fiscal 3Q18, Medtronic’s (MDT) MITG (Minimally Invasive Therapies Group) continued to perform poorly, reporting a YoY (year-over-year) decline of ~16% due to the divestiture of the company’s PMR (Patient Monitoring and Recovery) business in fiscal 2Q18. For details, please read Divestiture of a Part of Medtronic’s PMR Business to Cardinal Health. However, on a constant-currency […]

    By Sarah Collins
  • uploads///CVG
    Earnings Report

    What Drove Medtronic’s Cardiac and Vascular Group in 3Q18

    Cardiac and Vascular Group in fiscal 4Q17 Medtronic (MDT) reported total sales of ~$7.4 billion in fiscal 3Q18. Of that total, ~38% (~$2.8 billion) was contributed by Medtronic’s CVG (Cardiac and Vascular Group). CVG sales grew ~10% YoY (year-over-year) and ~7% on a constant-currency basis. US CVG sales grew ~6% YoY, while developed nation CVG sales […]

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts’ Latest Recommendations on Boston Scientific Stock

    BSX operates in three business segments: MedSurg, Rhythm Management, and Cardiovascular.

    By Sarah Collins
  • uploads///harpoon
    Company & Industry Overviews

    Edwards Lifesciences Expands Portfolio with Harpoon Medical Acquisition

    On December 6, 2017, Edwards Lifesciences (EW) announced the completion of its acquisition of Harpoon Medical for $100 million in cash on December 1, 2017.

    By Sarah Collins
  • uploads///acquisitions
    Company & Industry Overviews

    Stryker’s Inorganic Growth Strategy Continues to Boost Growth

    Stryker’s acquisition-driven growth strategy Stryker (SYK) has been growing at a fast pace through inorganic growth. It has undertaken a number of strategic acquisitions recently. In 3Q17, acquisitions contributed approximately 0.6% of the company’s YoY (year-over-year) sales growth, and in the first three quarters of 2017, Stryker acquisitions contributed ~3.2% of the company’s sales growth […]

    By Sarah Collins
  • uploads///lotus edge
    Company & Industry Overviews

    How Might BSX’s Delayed LOTUS Edge Impact Its Performance?

    According to Boston Scientific, the delay will have no material impact on the company’s fiscal 4Q17 and 2017 results.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Why Boston Scientific Stock Fell 9% in Two Days

    Boston Scientific (BSX) stock fell ~7.5% on November 28, 2017, triggered by the speculation of bad news.

    By Sarah Collins
  • uploads///mitg
    Company & Industry Overviews

    Medtronic’s Disappointing MITG Business Performance in Fiscal 2Q18

    Due to the disappointing fiscal 2Q18 results, Medtronic made a downward revision to its estimates for MITG sales growth in fiscal 2018 to 3.0%–3.5%.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Edwards Lifesciences: Analyst Recommendations in November

    In 3Q17, Edwards Lifesciences (EW) reported adjusted sales of ~$838 million, which is an underlying growth of ~13% on a YoY basis. This performance was driven by double-digit organic growth.

    By Margaret Patrick
  • uploads///medical pipeline
    Company & Industry Overviews

    What’s BD’s Latest News in the Diabetes Management Market?

    On September 19, 2017, Becton, Dickinson, and Company (BDX), or BD, introduced a new pen needle for its pen injection devices.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    HVAD Expected to Expand Medtronic’s Presence in LVAD Segment

    On September 27, 2017, the FDA approved Medtronic’s HVAD (HeartWare ventricular assist device) system as a destination therapy for advanced heart failure patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Focused on Efficacy and Safety of LVAD Offerings

    Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.

    By Margaret Patrick
  • uploads///heartlogic
    Company & Industry Overviews

    New Data Confirms the Efficiency of BSX’s HeartLogic Diagnostic

    On September 19, 2017, Boston Scientific announced new data from its MultiSENSE (Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients) study.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Diversified Growth Has Boosted MDT’s Cardiac and Vascular Segment

    In the first quarter of fiscal 2018, Medtronic (MDT) reported revenues close to $2.6 billion for its cardiac and vascular (or CVG) group, which is 5% year-over-year (or YoY) growth on a reported basis and 6% YoY growth on an operational basis.

    By Margaret Patrick
  • uploads///SAPIEN  DATA
    Company & Industry Overviews

    FDA Approvals Could Drive Edwards Lifesciences’ Growth

    On June 5, 2017, Edwards Lifesciences’ Sapien 3 valve was approved by the FDA for use in the aortic and mitral valve-in-valve procedure.

    By Sarah Collins
  • uploads///revenue guidance
    Company & Industry Overviews

    Edwards Lifesciences Near 52-Week High: Can It Sustain Momentum?

    Edwards Lifesciences (EW), a leader in the artificial heart valve market, has been expanding rapidly amid its new product launches and innovative product pipeline.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts Positive on Edwards Lifesciences: Most Recommend ‘Buy’

    Edwards Lifesciences (EW) had tremendous growth in the first half of 2017. The stock has been recovering from the lows in late 2016 and has recently been on a bullish trend.

    By Sarah Collins
  • uploads///STRATEGY
    Company & Industry Overviews

    Boston Scientific’s Expansion Plans in a Fast-Growing Market

    Boston Scientific (BSX) has been shifting its focus away from low-growth markets and is trying to enter the high-growth adjacent markets.

    By Sarah Collins
  • uploads///CATEGORY LEADERSHIP
    Company & Industry Overviews

    Boston Scientific Is Accelerating Category Leadership Strategy

    Boston Scientific (BSX) currently has a global market opportunity of $40.0 billion, which is expected to grow to $50.0 billion by fiscal 2020.

    By Sarah Collins
  • uploads///DIABETES SEGMENT PERFORMANCE
    Company & Industry Overviews

    MDT’s Diabetes Segment’s Supply Headwinds Expected to Impact Fiscal 2018

    In fiscal 1Q18, Medtronic’s (MDT) Diabetes Group reported revenues of $449 million, which represents a year-over-year sales decline of ~1%.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Edwards Lifesciences Focuses on Indication Expansion of SAPIEN 3 in 2017

    To further expand the label of its transcatheter heart valve (or THV), SAPIEN 3, Edwards Lifesciences (EW) is currently involved in enrolling patients in its EARLY-TAVR trial.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Edwards Lifesciences’ Mitral Regurgitation Segment

    To diversify its focus beyond aortic structural heart conditions, Edwards Lifesciences (EW) acquired CardiAQ Valve Technologies in August 2015.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Edwards Lifesciences Focuses on Launch of SAPIEN 3 Ultra and CENTERA Valves

    Edwards Lifesciences’ (EW) SAPIEN 3 Ultra system is a next-generation platform, with expandable Axela sheath technology and on-balloon delivery design.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Edwards Lifesciences: Focused on Inspiris Resilia and Konect

    To extend the durability of the Inspiris Resilia surgical aortic valve, Edwards Lifesciences (EW) has incorporated a new tissue platform, Resilia tissue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Can Edwards Intuity Elite Boost Edwards Lifesciences’ Revenues?

    With the Edwards Intuity Elite valve system, Edwards Lifesciences aims to offer a minimally invasive therapy to complex aortic stenosis patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    TAVR Therapy Expected to Witness Solid Growth in Demand in 2017

    Demand for transcatheter aortic valve replacement (or TAVR) therapy has been robust in the US, mainly due to the opening of new heart valve centers and relatively lower competition.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Transcatheter Heart Valve Therapy: Growth Driver for Edwards Lifesciences

    In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%.

    By Margaret Patrick
  • uploads///margin
    Earnings Report

    Medtronic’s Strong 4Q17 Profits Beat Analyst Expectations

    Medtronic (MDT) reported an operating margin of 30.7% of total sales in fiscal 4Q17 on a constant currency basis.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Do Analysts Recommend for Boston Scientific?

    Let’s look at Wall Street analysts’ recommendations and target prices for Boston Scientific (BSX) over the next 12 months.

    By Sarah Collins
  • uploads///resonate approval
    Company & Industry Overviews

    BSX’s Resonate ICD and CRT-D Defibrillators Get US Approval

    On May 9, 2017, Boston Scientific (BSX) announced the FDA approval of its Resonate family of products, including its ICD and CRT-D systems.

    By Sarah Collins
  • uploads///stock
    Company & Industry Overviews

    Discussing Boston Scientific Stock’s Recent Movements

    Boston Scientific (BSX) was trading at $27.2 on May 25, 2017. It had a 50-day moving average of $25.8 and a 200-day moving average of $23.9.

    By Sarah Collins
  • uploads///strategic initiatives
    Company & Industry Overviews

    Behind BD’s Recent Strategic Initiatives and Product Launches

    In its diabetes business, BD (BDX) is working with Medtronic (MDT) to relaunch a new infusion set, after the temporary suspension of its shipments.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Recent Developments

    Novartis (NVS) reported flat revenues at constant exchange rates during 4Q16 as well as in fiscal 2016. This was driven by growth in Sandoz revenues.

    By Mike Benson
  • uploads///medical pipeline
    Company & Industry Overviews

    Analyzing the BD Medical Segment’s Product Pipeline

    Becton, Dickinson and Company (BDX) generates ~$1 billion from its Infection Prevention business.

    By Sarah Collins
  • uploads///structural heart
    Company & Industry Overviews

    New Structural Heart Initiatives: Edwards’ Key Growth Drivers in 2017 and Beyond

    Edwards Lifesciences estimates that mitral regurgitation patients total 2.5 million–3.5 million. But only ~25,000 patients per year are treated in the US.

    By Sarah Collins
  • uploads///valtech cardio
    Company & Industry Overviews

    Edwards Lifesciences’ Acquisition of Valtech Cardio: Must-Know Details

    On November 28, 2016, Edwards Lifesciences (EW) announced the acquisition of Valtech Cardio for $340 million in stock and cash.

    By Sarah Collins
  • uploads///product pipeline
    Company & Industry Overviews

    Inside Edwards Lifesciences’ THV Product Pipeline and Future Growth Estimates

    Edwards Lifesciences (EW) has a robust product pipeline in its THV (transcatheter heart valve) segment, with Sapien 3 as the segment’s leading product.

    By Sarah Collins
  • uploads///segments
    Company & Industry Overviews

    Trial Data Affirms Positive Results of HeartLogic Diagnostic Service

    Developed by Boston Scientific (BSX), HeartLogic is a system of sensors that can be attached to defibrillator devices. These sensors can monitor the patient and predict heart failure events.

    By Sarah Collins
  • uploads///Series  A
    Miscellaneous

    What You Need to Know About the Micron-Inotera Deal

    A major part of Micron Technology’s (MU) transition to the 20 nm node involves Taiwan’s (EWT) Inotera and its joint venture with Nanya Technology.

    By Puja Tayal
  • uploads///cvg
    Earnings Report

    Understanding Medtronic’s Weak CVG Segment Performance in Fiscal 2Q17

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.6 billion came from Medtronic’s CVG segment, representing ~35% of the company total.

    By Sarah Collins
  • uploads///projections
    Earnings Report

    Edwards Lifesciences Updates 2016 Guidance after 3Q16 Earnings

    Edwards Lifesciences revised its 2016 guidance after reporting a strong 3Q16. The company maintained its sales guidance for the year at the high end of the $2.7 billion–$3 billion range.

    By Sarah Collins
  • uploads///PROFITABILITY
    Earnings Report

    How EW’s Gross Profit Margins Were Affected in 3Q16

    Edwards Lifesciences (EW) reported falling revenue in 3Q16. Its gross profit margin fell and was reported to be ~72.8% of its total revenue, compared to ~76.2% in 2Q16.

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    Boston Scientific’s 3Q16 Earnings Beat Analysts’ Estimates

    Boston Scientific (BSX) reported its 3Q16 earnings on October 26, 2016. It registered adjusted EPS of $0.27 in 3Q16. It had ~12.5% YoY growth.

    By Sarah Collins
  • uploads///valiant captivia
    Company & Industry Overviews

    New Data Affirm Benefits of Medtronic’s Valiant Captivia

    On September 20, 2016, Medtronic posted its new safety and efficacy data for its Valiant Captivia Thoracic Stent Graft System.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Profitability Improves, Allowing for Revised Guidance

    Incyte (INCY) reported revenues of $246.3 million in 2Q16, an increase of 51% compared to $163 million in 2Q15.

    By Mike Benson
  • Company & Industry Overviews

    What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?

    The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.

    By David Ashworth
  • uploads///segment performance
    Earnings Report

    Analyzing Medtronic’s Sales Growth by Segment in 1Q17

    Medtronic (MDT) operates under four segments: Cardiac and Vascular Group (or CVG), Minimally Invasive Therapies Group (or MITG), Restorative Therapies Group (or RTG), and Diabetes Group.

    By Sarah Collins
  • uploads///part
    Company & Industry Overviews

    How Are Danaher’s Returns Compared to Its Industry Peers’?

    Danaher’s ROIC fell steadily from 15.5% in 2006 to 8.5% in 2015, indicating that it has probably had fewer high return reinvestment opportunities since then.

    By Shannon Black
  • uploads///mitg
    Company & Industry Overviews

    Medtronic’s Minimally Invasive Therapies Group: Major Drivers

    Medtronic plans to launch more than 80 products over the next three years.

    By Sarah Collins
  • uploads///cvg structure
    Company & Industry Overviews

    What Drives Medtronic’s Cardiac Vascular Group’s Revenues?

    Medtronic’s (MDT) Cardiac and Vascular Group (or CVG) is its largest segment.

    By Sarah Collins
  • Company & Industry Overviews

    How the Healthcare Sector Has Hurt ELGAX Year-to-Date in 2016

    On May 27, 2016, the Columbia Select Large Cap Growth Fund Class A (ELGAX) had fallen by 6.5% YTD (year-to-date) in 2016.

    By David Ashworth
  • uploads///segment revenues
    Earnings Report

    How Did Edwards Lifesciences’ Critical Care Segment Fare in 1Q16?

    Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$134 million was contributed by the company’s Critical Care segment.

    By Sarah Collins
  • uploads///revenue segmentation
    Company & Industry Overviews

    St. Jude Medical’s Market Position and Opportunities

    St. Jude Medical has a comprehensive product portfolio in the atrial fibrillation and heart failure therapy areas. The acquisition of Thoratec added to its heart failure therapy product segment.

    By Sarah Collins
  • uploads///TRIAL RESULTS
    Company & Industry Overviews

    A Look at Edwards Lifesciences’ Future Opportunities

    Currently, Edwards Lifesciences’ Sapien 3 and Sapien XT are approved by the FDA to be used in high-risk patients only.

    By Sarah Collins
  • uploads///projections
    Earnings Report

    Stryker’s 4Q15 Revenues Expected to Witness Growth

    Wall Street has estimated Stryker’s 4Q15 revenues to be about $2.7 billion, representing a growth of around 3.6% on a YoY (year-over-year) basis compared.

    By Sarah Collins
  • uploads///risks
    Company & Industry Overviews

    Medtronic Faces Risks from Integrating with Covidien

    Medtronic is a highly diversified company in terms of geographic exposure. Some of the risks faced by Medtronic include integration and litigation risks.

    By Sarah Collins
  • uploads///latest technologies impacting medical device industry
    Company & Industry Overviews

    Why Technology Is a Key Driver in the US Medical Device Industry

    Traditionally, the United States has been home to the most advanced technological inventions in the medical device industry.

    By Sarah Collins
  • uploads///key components of Reimbursement
    Company & Industry Overviews

    How Reimbursement Models Impact the Medical Device Industry

    Coverage, coding, and payment are essential elements to obtaining adequate reimbursement for a new medical device.

    By Sarah Collins
  • uploads///ardiovascular segmentation
    Company & Industry Overviews

    Evaluating Medtronic’s Cardiac and Vascular Devices Segment

    Medtronic’s Cardiac and Vascular segment consists of Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular.

    By Sarah Collins
  • uploads///cardiovascular device segments
    Company & Industry Overviews

    How Are Cardiovascular Devices Classified?

    The US cardiovascular device market is dominated by cardiac rhythm management (or CRM) devices.

    By Sarah Collins
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Nuvasive Traded above Its 100-Day Moving Average

    Nuvasive (NUVA) gained 1.3% on October 12, 2015. The stock went up on the news that the FDA gave clearance for NUVA’s cervical corpectomy cage.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    How are XLV’s Moving Averages Trending?

    Out of 56 stocks in XLV’s portfolio, a total of 32 stocks were trading above their 20-day moving average.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XLV Gained 1% as 60% of Portfolio Ended Positively for the Day

    XLV outperformed the broader market representative SPDR S&P 50 ETF on October 1, 2015. SPY rose by 0.26% , compared with XLV’s 1.01%.

    By Peter Neil
  • uploads///Performance of SPYs Component Sectors
    Macroeconomic Analysis

    Healthcare Sector Recovery, Led ETF by 0.92%

    The healthcare sector rebounded on Tuesday, September 29, after being rattled the week prior.

    By Renee Blakely
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.